The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; 2 of the 17 sources its claims cite were checked for support.
Clinical implications of discordance between anti-dsDNA antibodies by multiplex flow immunoassay and Crithidia luciliae assay in a multiethnic racial cohort of patients with SLE
Open accessAbstract
OBJECTIVE: immunofluorescence test (CLIFT). To address the clinical impact of measuring these antibodies by two different assays, this study leveraged a well-phenotyped multiethnic/racial cohort. METHODS: All patients fulfilled the classification criteria for SLE by at least one of the validated schemes: American College of Rheumatology, Systemic Lupus Erythematosus International Collaborating Clinics and/or American College of Rheumatology/European League Against Rheumatism classification criteria. Patients with one or more simultaneously paired anti-dsDNA by multiplex EIA and CLIFT were identified. Analysis of concordance or discordance, titre comparability of assays and association with hybrid SLE Disease Activity Index score, prevalence of lupus nephritis (LN), ability to predict a flare and classification criteria was performed. RESULTS: 207 patients were simultaneously tested by EIA and CLIFT at least once for anti-dsDNA, generating 586 paired results. 377 pairs were concordant and 209 were discordant. 41 of 207 patients always had discordant paired results and 39 patients always had results with titre discordance. In 100 patients with LN, 60 were positive by EIA and 72 by CLIFT. Sensitivities and specificities for patients with LN versus patients without LN were EIA 60% and 47%, and CLIFT 72% and 37%, respectively. 42 patients had flare assessment within 90 days of their paired result. Six of seven patients with mild flares and all four patients with severe flares had concordant positive results. CONCLUSION: Our data demonstrate that discordance of positivity between both assays for anti-dsDNA is relatively common, occurring in a fifth of patients overall and a third of visits. EIA positivity is associated with LN less often than CLIFT positivity. With the significant discordance of results between anti-dsDNA assays, obtaining both CLIFT and EIA assays may be beneficial for classification and routine monitoring of SLE.
Overview
CoChat Summary
## TL;DR
This retrospective cohort study in 207 patients with SLE found that anti-dsDNA results by multiplex EIA and CLIFT were frequently discordant: 36% of 586 paired results and 20% of patients had discordant positivity. EIA positivity was less associated with lupus nephritis than CLIFT positivity, and the authors conclude that using both assays may help with diagnosis and routine monitoring.
## Key findings
- Among 207 patients, there were 586 paired anti-dsDNA results; 377 pairs (64%) were concordant and 209 (36%) were discordant.
- At the patient level, 41 of 207 patients (20%) were always discordant; including fluctuating cases, 88 patients had discordant results at least once.
- In 100 patients with lupus nephritis (LN), 60 had at least one positive EIA result and 72 had at least one positive CLIFT result; sensitivity/specificity were 60%/47% for EIA and 72%/37% for CLIFT.
- Among 250 positive concordant paired results, 141 (56%) had titre discordance; 39 of 98 patients (40%) with these positive concordant results always had titre discordance.
- For flare prediction, 42 patients had assessment within 90 days: 6 of 7 mild flares and all 4 severe flares had concordant positive results before the flare.
## Methods
- Retrospective analysis of a diverse New York University Lupus Cohort of patients with SLE seen at NYU Langone Health and Bellevue Hospital Center since 2014.
- Included 207 patients who had one or more simultaneous paired anti-dsDNA tests by multiplex EIA and CLIFT; analyses used 586 paired results.
- Compared assay concordance/discordance, titre concordance, hybrid SLEDAI scores, LN prevalence and test characteristics, flare prediction within 90 days, and whether anti-dsDNA positivity affected classification criteria; sensitivity, specificity, PPV, and NPV were calculated.
## Limitations
- Stated by the paper: only the multiplex EIA was studied, not other EIA methods; test selection was not protocolised and depended on the ordering provider; titre tertiles were arbitrarily defined; LN classification may have reflected prior damage rather than active nephritis; not all LN patients had both tests; flare analysis had limited power because only 9% of paired visits had a follow-up encounter within 90 days.
- Evident from the text: this was a retrospective observational study, so associations cannot establish causality.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
0 Valid · 2 Not valid · 6 Not checked · 38 Own results and interpretations
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“serial measurement of anti-dsDNA is often used to monitor lupus disease activity, especially lupus nephritis (LN).”
§ Clinical implications of discordance between anti-dsDNA antibodies by multiplex flow immunoassay and Crithidia luciliae assay in a multiethnic racial cohort of patients with SLE > Introduction
What the sources say
- Not checked — no full text of the sourcecites [3] source
- Not checked — no full text of the sourcecites [4] Ghirardello, 2011, Diagnostic accuracy of currently available anti-double-stranded DNA antibody assays, Clin Exp Rheumatol
- Could not verifycites [5] sourceExperimental — accuracy not yet measured
The Introduction (pp. 607–608) discusses antibodies and immune complexes in lupus nephritis, and the Discussion (around p. 620) mentions anti-DNA antibodies in a few patients with active SLE. Neither passage addresses whether serial anti-dsDNA measurement is often used to monitor disease activity or lupus nephritis; searches for serial testing and clinical monitoring found no such passage. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“positive anti-dsDNA is an important component of the classification criteria for diagnosing SLE”
§ Clinical implications of discordance between anti-dsDNA antibodies by multiplex flow immunoassay and Crithidia luciliae assay in a multiethnic racial cohort of patients with SLE > Introduction
What the sources say
- Not checked — no full text of the sourcecites [3] source
- Not checked — no full text of the sourcecites [4] Ghirardello, 2011, Diagnostic accuracy of currently available anti-double-stranded DNA antibody assays, Clin Exp Rheumatol
- Could not verifycites [5] sourceExperimental — accuracy not yet measured
The Introduction (p. 607) and the summary discuss anti-DNA antibodies in SLE nephritis and their possible role in renal injury. Neither addresses whether a positive anti-dsDNA test is part of SLE classification criteria. Searches for classification criteria and diagnostic use found no relevant passage in our copy. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Two patients with a low titre positive EIA and negative CLIFT would not have met the classification criteria for diagnosis of SLE by ACR, SLICC, or 2019 ACR/EULAR without the positive anti-dsDNA result by EIA.”
§ Clinical implications of discordance between anti-dsDNA antibodies by multiplex flow immunoassay and Crithidia luciliae assay in a multiethnic racial cohort of patients with SLE > Results > EIA and CLIFT association with classification criteria
hedgedstates a causen = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of these visits, 11 were classified as flares”
§ Clinical implications of discordance between anti-dsDNA antibodies by multiplex flow immunoassay and Crithidia luciliae assay in a multiethnic racial cohort of patients with SLE > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The opposite pairing of a high titre EIA and low titre CLIFT had a mean SLEDAI of only 3.”
§ Clinical implications of discordance between anti-dsDNA antibodies by multiplex flow immunoassay and Crithidia luciliae assay in a multiethnic racial cohort of patients with SLE > Results > EIA and CLIFT association with hybrid SLEDAI score
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
17 more claims
Create a free account to see all 46 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 18
- The quote only partly states this claim. 2
- Probably not a substantial claim. 8
Citations
Cites
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Petri, M., Orbai, A., Alarcón, G. S., Gordon, C., Merrill, J. T., Fortin, P. R., Bruce, I. N., Isenberg, D., Wallace, D. J., Nived, O., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34473 · Cited by 5,322
Self-citationAringer, M., Costenbader, K., Daikh, D., Brinks, R., Mosca, M., Ramsey‐Goldman, R., Smolen, J. S., Wofsy, D., Boumpas, D. T., Kamen, D. L., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40930 · Cited by 2,677
Self-citationIMMUNOLOGICAL STUDIES CONCERNING THE NEPHRITIS OF SYSTEMIC LUPUS ERYTHEMATOSUS
Koffler, D., Schur, P. H., & Kunkel, H. G. (1967) · The Journal of Experimental Medicine · doi:10.1084/jem.126.4.607 · Cited by 879
Buyon, J. P., Petri, M. A., Kim, M. Y., Kalunian, K. C., Grossman, J., Hahn, B. H., Merrill, J. T., Sammaritano, L., Lockshin, M., Alarcón, G. S., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00004 · Cited by 661
Self-citationTer Borg, E. J., Horst, G., Hummel, E. J., Limburg, P. C., & Kallenberg, C. G. M. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330505 · Cited by 572
Classification and definition of major flares in SLE clinical trials
Petri, M., Buyon, J., & Kim, M. (1999) · Lupus · doi:10.1191/096120399680411281 · Cited by 282
Self-citationAnti-DNA antibodies–quintessential biomarkers of SLE
Pisetsky, D. S. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.151 · Cited by 267 · cited 1×
“20 21 Alternatively, discordance could be caused by circulating factors that modify the antigen target and produce false positives (ie, LDL/IgG complexes that non-specifically bind to the Crithidia flagellate).”
BackgroundGuidelines for immunologic laboratory testing in the rheumatic diseases: Anti‐DNA antibody tests
Kavanaugh, A. F., Solomon, D. H., & The American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines (2002) · Arthritis Care & Research · doi:10.1002/art.10558 · Cited by 225
Bio-Rad’s Bio-Plex® suspension array system, xMAP technology overview
Houser, B. (2012) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2012.705301 · Cited by 202
Research works printed but not linked: 3
- Kunkel HG . Advances in immunology. New York London: Academic Press, 1982.
- Ghirardello, 2011, Diagnostic accuracy of currently available anti-double-stranded DNA antibody assays, Clin Exp Rheumatol, 29, 50
- 10.1016/j.cca.2011.02.025 · DOI
Cited by
Lupus nephritis: redefining the treatment goals
Vriese, A. S. D., Sethi, S. M., & Fervenza, F. C. (2024) · Kidney International · doi:10.1016/j.kint.2024.10.018 · Cited by 69
Psoriasis and Lupus Erythematosus—Similarities and Differences between Two Autoimmune Diseases
Fijałkowska, A., Wojtania, J., Woźniacka, A. J., & Robak, E. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13154361 · Cited by 12
Ricchiuti, V., Obney, J., Holloway, B., Aure, M. A., Shapiro, M., Bentow, C., & Mahler, M. (2025) · Diagnostics · doi:10.3390/diagnostics15192430 · Cited by 3
“Furthermore, these assays are quantitative, a valuable feature considering that antibody levels may provide additional clinical insight [21].”
Clinical evaluation of the novel digital liquid chip method for anti-dsDNA detection in SLE
Bai, Y., Yu, R., Xue, C., Wang, Q., Tian, X., Zeng, X., Li, M., & Hu, C. (2025) · Lupus Science & Medicine · doi:10.1136/lupus-2025-001608 · Cited by 1
Transcriptome integration analysis of shared biomarkers and common immune mechanisms in SLE and PSO
Cheng, M., Pei, Y., Li, B., et al. (2026) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2026.105886
Metadata
- Authors
- Zaminski, D., Saxena, A., Izmirly, P., Buyon, J. P., & Belmont, H. M.
- Affiliations
- NYU Langone Health (US)
- New York University (US)
- Corresponding author
- Zaminski, Devyn
- Venue
- Lupus Science & Medicine
- Publisher
- BMJ
- Published
- 2023-11
- Volume
- 10
- Issue
- 2
- Pages
- e001012
- ISSN
- 2053-8790 (ISSN-L)
- PMC
- PMC10649789
- OpenAlex
- W4388706765
- Cited by
- 5
- References
- 26
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Lupus Science & Medicine (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Keywords
- systemic lupus erythematosus, anti-dsDNA antibodies, assay concordance, lupus nephritis, disease flare prediction, SLE classification criteria, multi-ethnic cohort
- MeSH terms
- Antibodies, Antinuclear, Crithidia, DNA, Fluorescent Antibody Technique, Humans, Immunoassay, Lupus Erythematosus, Systemic, Lupus Nephritis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical implications of discordance between anti-dsDNA antibodies by multiplex flow immunoassay and Crithidia luciliae assay in a multiethnic racial cohort of patients with SLE. https://app.cochat.ai/papers/10.1136/lupus-2023-001012
- The paper
- Zaminski, D., Saxena, A., Izmirly, P., Buyon, J. P., & Belmont, H. M. (2023). Clinical implications of discordance between anti-dsDNA antibodies by multiplex flow immunoassay and Crithidia luciliae assay in a multiethnic racial cohort of patients with SLE. Lupus Science & Medicine. https://doi.org/10.1136/lupus-2023-001012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
